3i Diagnostics, Inc.3i Diagnostics (3iDx) is a precision medicine diagnostic platform for infectious diseases. The initial focus is to launch an instrument / assay that is able to identify the species of microbial infection from whole blood within one hour of taking the blood sample with no need for blood culturing.
7 Hills Pharma LLC7 Hills is developing novel immuno-modulators to treat solid tumors based on commercially validated co-stimulatory molecules. Our lead product, 7HP349, may increase the effectiveness of immune checkpoint inhibitors.
Solid tumors of the skin, lung and pancreas are resistant to conventional chemotherapy and emerging immunotherapies. Resistance is mediated by the inability to effectively activate and mobilize the immune system. Immune checkpoint inhibitors such as Yervoy and Opdivo provide durable responses in only 1 in 5 patients because of the lack of tumor infiltration and killing by effector cells. 7 Hills is developing novel means to increase the penetration of cytolytic cells into solid tumors and facilitate killing. By converting "cold" tumor to "hot", 7HP349 has shown remarkable activity in aggressive models of PDL-1 negative tumors. We are currently looking for R&D partner(s) to file an IND, initiate a Phase I/IIa study. Our management is comprised of experienced executives and oncologists that have developed 5 new drugs from molecule to market.
We are currently raising our first institutional round of $20-25 million.
AboGenAboGen’s mission is to: enable and accelerate the shift from the use of blood to the use of saliva for diagnostic purposes.
AboGen is the first company to have capitalized on the similarities of blood and saliva by developing proprietary technologies for the collection, preservation and isolation of ALL the components of saliva; from the extracellular material (serum proteins, exosomes, cell free DNA, bacteria, viruses) to the cells themselves (including white blood cells, including specific T-cell populations, buccal cells and epithelial cells). This technology will cause a paradigm shift in the in-vitro diagnostic (IVD) field by enabling many diagnostics performed today from blood to be performed tomorrow from saliva (80% of the 5B blood tests in the US alone).
Abreos BiosciencesBiologic therapies are the largest growth segment of the pharmaceutical industry. Biologic therapeutics are often used for long-term management of chronic diseases and have been very successful in mitigating these conditions. However, due to the formation of anti-drug antibodies (ADA) and the pharmacokinetic (PK) variability in the same individual and between individuals, the clinical response to biologic drugs is highly heterogeneous. The relationship between serum drug concentration and clinical efficacy is critical. Although dosing regimens differ somewhat depending on the clinical indication being treated, dosing in patients is mostly a one-dose-fits-all approach despite the significant variation in how different individuals process these drugs.
Abreos Biosciences’ Veritope tests for point-of-care measurement of circulating blood concentrations of active biologic drug would provide a simple and inexpensive solution that addresses this real clinical need. The Veritope tests can be used to not only help physicians personalize the accurate dosing of their patients, but will assist biologic drug developers to maximize the therapeutic outcomes of their biologic drugs and to improve the success of clinical trials by stratifying patients to identify those most likely to benefit.
Abreos Biosciences’ core enabling technology platform is based on mimetope peptides, termed Veritopes, that mimic the cognate ligand of a given monoclonal antibody drug (mAb) and specifically bind at the antigen binding site. These peptides are ideal immunoassay reagents and can be implemented in point-of-care (POC) lateral flow based assays (LFA). Direct monitoring of drug levels enables precise, personalized dosing regimens that improve clinical outcomes and minimize side effects. This test will be suitable not only for detection of the original version of biologic therapies but also for any biosimilar entering the market. Health care practitioners can use the Veritope LFA testing system at the infusion clinic, emergency room, or doctor’s office and generate quantitative measurements at the point-of-care using a single drop of blood in 20 minutes or less. The Veritope LFA tests are also ideal for home use by patients taking injectable drugs. The testing system is a digital and connected health solution that can send information directly to the patient’s smartphone or cloud-based EHR system.
Adjuvance TechnologiesAdjuvance Technologies is helping protect life by modernizing vaccine adjuvant design and manufacturing. Our lead adjuvants have the ability to 1) enhance existing vaccine programs by providing an attractive alternative to the botanical extract QS-21, 2) improve the immunogenicity of existing vaccines and 3) provide for the emergence of new vaccines that would benefit from the inclusion of an improved adjuvant.
Aethlon Medical, Inc.Aethlon Medical (Nasdaq:AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.
AlleCures IncAlleCures is seeking investment and partners for its Intra-Lymphnode Immunotherapy (IL-AIT) product candidates, which include allergens and devices in clinical development. IL-AIT uses ultrasound to guide, document and standardize delivery of allergens into individual lymphnodes. IL-AIT is safe and effective with low doses of allergens. AlleCures is standardizing IL-AIT and the ultrasound guided injection causes less pain than venous puncture, enables dose-sparing, rapid, clinically effective and safe immune responses, which correlate directly and positively with durable clinical immunotherapy outcomes.
AlleCures is seeking investments and partnership(s) to conduct clinical studies for pollen allergen desensitization by IL-AIT (i.e., 3 low dose pollen allergen shots administered via a lymphnode injection, every 2 weeks over 2 months with 100% compliance), where IL-AIT has achieved clinical proof of concept and enables greater safety, speed and allergy patient compliance directly compared to subcutaneous allergy immunotherapy (i.e., 50-80 high dose pollen allergen shots administered via subcutaneous injection over 3-5 years with 10-15% compliance).
Amplyx PharmaceuticalsAmplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The company’s lead compound, APX001, entered Phase 1 clinical development this year.
Amplyx licensed APX001 from Eisai Co., Ltd in 2015. APX001 has been evaluated extensively in preclinical studies, and has demonstrated broad-spectrum activity against infections caused by common species of Candida and Aspergillus, as well as activity against rare, hard-to-treat molds including Fusarium, Scedosporium and fungi from the Mucorales order. Patients with compromised immune systems due to chemotherapy or other immune-compromising medical treatments are susceptible to these potentially deadly fungal infections, and there are over 600,000 cases of invasive fungal infections due to Candida and Aspergillus and rare molds annually worldwide. Amplyx is developing both IV and oral formulations of APX001 to address the need for hospital administration, as well as continued dosage after hospital discharge.
Amplyx has raised $51.5 million in venture capital and received more than $10 million in grants from the National Institutes of Health to support its drug discovery and development efforts. The company’s research operations are located at Johnson & Johnson Innovation, JLABS in San Diego, Calif.
AMP PharmaceuticalsDescription: Research state company focused on new drugs against rare diseases caused by pathologic cell growth. Diseases we address are dyskeratosis congenita, idiopatic pulmonary fibrosis (genetic type), aplastic anemias, fragile X syndrome, some rare tumors, etc. All our active principles are patented and we own all IP rights in exclusivity.
We seek $ 23 million to enter 2 clinical trials. We also seek potential industry partners to codevelop some of our drugs.
Company relocating to California in 2017.
Company owned by founders.
Angiocrine Bioscience, Inc.Angiocrine Bioscience Inc. is a private biopharmaceutical company located in San Diego, California applying its patented E-CEL Technology to develop a new class of therapeutics for multiple inherited hematologic (blood system) diseases and to restore damaged organs, starting with lung regeneration and tendon restoration.
Angiocrine’s lead therapeutic candidate (AB-110) is being prepared for a clinical trial in 2017 for the purpose of rebuilding the blood forming organs (e.g., bone marrow) and the immune system in children and adults who are treated with high-dose radiation and chemotherapy for life-threatening high-risk blood cancers. We also have a growing pipeline of biopharmaceutical therapies aimed to treat serious, mostly life-threatening disease with no effective treatments.
The company’s proprietary E-CEL Technology Platform is applicable to the regeneration and restoration for virtually every organ and is therefore a product engine for developing multiple, unique and groundbreaking cellular therapies. We have also developed proprietary methods for improving gene therapy, which has applications to thousands of inherited “Orphan” diseases.
Funded from inception by private equity from family offices based in the United States, the company seeks additional capital to further accelerate development of multiple therapeutic candidates into clinical trials and also to achieve corporate partnerships. With its novel scientific insights and potentially transformative technology and therapeutic candidates, Angiocrine Bioscience represents a unique investment opportunity with a potentially explosive valuation growth story.
Anven AlzDx Inc.Early Detection of Alzheimer’s Disease And Potential New Pathways to Treatment and Cures.
Anven’s biomimetic chemistry enables pre-symptomatic early detection of
Alzheimer’s and isolates disease-specific pathogenic molecules. A crucial
application can help therapeutic developers predict drug responders and
non-responders to improve selection of subjects for clinical trials. Anven
seeks to collaborate with drug developers for Alzheimer’s disease (AD) to
characterize patient populations with prognostic information regarding
disease progression unobtainable with current alternatives. Once
calibrated, a simple blood test quantifies intensity of target molecules or
state of disease. The blood test results clearly differentiate between
pre-symptomatic MCI patients and non-AD dementia patients. Similar
chemistry is leading to isolation of disease-specific pathogenic molecules
to provide explicit targets for further drug development. Anven is a
private company offering an information service to clinical trial sponsors
that need to better refine patient selection to likely responders.
Aphios CorporationAphios (www.aphios.com) is a clinical stage biotechnology company developing enabling technology platforms and utilizing these platforms to develop enhanced therapeutics for improving quality-of-life, and treating chronic diseases such as cancers, infectious diseases such as HIV, and Central Nervous System disorders such as Alzheimer's disease and Multiple Sclerosis in an environmentally sustainable manner.
Aphios, "virus-free" in Greek, was founded in 1993 as a Delaware corporation. Since our founding, we have researched the viral safety of biologics, the nanotechnology delivery of drugs and investigated natural therapeutics from medicinal plants and marine organisms. This revolutionary research has led to the realization that in order to solve the problems of cancer and aging, we should seek solutions from nature, marine organisms and terrestrial plants that have learned how to control cellular growth and cancerous mutation, often living for hundreds to thousands of years.
Apricus Biosciences, Inc.Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. The company is currently engaged in the commercialization of its EU-approved topical gel for erectile dysfunction, Vitaros in EU, LatAm, Canada, and select Middle Eastern countries. Apricus intends to resubmit its NDA to U.S. approval of Vitaros in Q4 2016 with approve expected by mid 2017. Vitaros is locally applied and contains alprostadil plus our novel excipient. The company is also developing RayVa, a topical cream for Raynaud's phenomenon is patients suffering from scleroderma, and seeking an ex-U.S. development partner.
AptamiR Therapeutics, Inc.AptamiR's MISSION is to cure human obesity by activating thermogenesis without altering brain and cardiovascular functions or quality of life.
Our STRATEGY is:
♦ To target peripheral fat-storing white adipocytes to transform them into fat-burning adipocytes (“Browning Effect”)
♦ To focus on miRNAs which modulate many target genes and pathways
♦ Human obesity is a costly pandemic affecting 1/3 of the world population
♦ Current medical treatments of obesity have poor benefit-to-risk profiles, fail to reach long-term therapeutic goals and do not meet patients’ expectations
♦ Since inception in 2012, AptamiR has developed a modular R&D platform leading to the selection of its first drug candidate (APT-110) for the treatment of obesity and diabetes, which is expected to reach clinical testing by the end of 2016
♦ Breakthrough results were achieved in mouse model of Diet-Induced Obesity:
o Body weight and fat mass reduction (12% after 12 weeks of treatment) despite steady consumption of 60% fat diet
o Energy expenditure increase
o Glucose tolerance and insulin sensitivity normalization
o Serum cholesterol, pro-inflammatory leptin, and liver mass reduction
♦ AptamiR filed several patent applications in various geographic regions:
o First US patent 9,034,839 B2 (May 2015): “MicroRNA modulators of thermogenesis”
o US Patent 2015-0216892-A1 (August 2015): “Cell-specific delivery of miRNA modulators for the treatment of obesity and related disorders”
o US Patent 62/329,537 (April 2016): Inhibition of mir-22 miRNA by APT-110
♦ The FDA positively reviewed AptamiR’s first pre-IND application in January 2015. A full IND application will be filed in December 2016
AptamiR completed 3 rounds of Angels Financing and Series A Financing, raising a total of $5.7M
AptamiR now aims to raise $10M in order to:
♦ To reach Phase 2 clinical development of our 1st drug candidate and start clinical development for 2nd drug candidate
♦ Further develop our unique delivery platform targeting adipose tissues
♦ Marc Thibonnier, MD, MSc, founded AptamiR after a successful career in Academia and Pharmaceutical Companies
Board Members and Scientific Advisors include: Philippe Camus: Chairman of AptamiR and Alcatel-Lucent/Nokia, Jean-Pierre Lehner, MD: Retired Chief Medical Officer of Sanofi, John Amatruda, MD: Former SVP and Head of Diabetes and Obesity at Merck Research Laboratories, Bernard Poussot: Retired Chairman, CEO & President of Wyeth
Arch Therapeutics, Inc.The Mission of Arch Therapeutics is to develop products that will improve the lives of patients and enhance the quality of care offered by healthcare personnel. We intend to offer compelling options to healthcare institutions facing limited resources.
Arch Therapeutics strives to be a leader in the field of stasis and barrier applications. This includes, but is not limited to, hemostasis and sealant products. We intend to develop products with dramatically improved profiles and characteristics over products on the market or in development.
Arch Therapeutics is focused on capital efficiency. Our operational plans are geared toward achieving value-creating milestones in a manner that optimizes quality, probability of success, and cost effectiveness.
Argos Therapeutics, Inc.Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.
ASDERAASDERA develops repurposed and reformulated drugs for diseases in urgent need of treatment by identifying genetic risk factors for complex diseases from publicly available data. ASDERA's unique advantage is a computational biostatistics platform (US Pat. 7,664,616) that can identify novel drug targets from genetic data of only 100s, rather than 100,000s of subjects. The current lead (below) is a single phase 3 trial away from market.
Pipeline: ASDERA's platform has been validated by confirming most known drug targets in epilepsy (2013, Pharmacogenomics). As a proof-of-principle it identified a rare sugar (L-fucose) as a nutritional supplement in Crohn's disease. The current lead is an ester-prodrug of mefenamic acid (orphan drug, pat. pending) to prevent 20,000 US children per year who develop autism from becoming non-verbal (2014, Nature: Translational Psychiatry). The next-in-line is a drug (pat. pending) against metastases in breast cancer. Because the platform identified a common component in the etiology as a target, the same drug may be effective in preventing plaque formation in Alzheimer's and Parkinson's.
Second market: The platform has also been validated to identify genetic risk factors for treatment failure in phase 3 trials and can also be used to select study populations most likely to respond from phase 2 data.
Attenua, IncAttenua is developing non-narcotic prescription therapies for acute and chronic coughs. Cough is a neglected medical problem in which novel therapies, either alone or in combination, have blockbuster potentials.
Cough is the #1 reason for outpatient visits in the US with >28M visits per year, or 3% of all visits. More than 30 million prescriptions are written for cough medications in the US alone each year. Approximately 80% of these scripts are for drugs with serious abuse potential including narcotics and dextromethorphan. No new prescription cough medicines (NCEs/NMEs) have been approved by the FDA since 1958. The currently approved drugs have limited evidence of efficacy. Furthermore, the FDA is trying to minimize the use of narcotics due to their abuse.
Attenua recently purchased 3 small molecule ready for Phase 2. These molecules have been previously tested in >1200 patients for other indications. All molecules have been clinically characterized for safety and PK/PD. In Phase 1 and 2 studies, these molecules demonstrated placebo-like safety profiles suitable for such an indication as cough. We have compelling animal and supportive human data suggesting one of these molecules (ATA-101) will be effective as cough-suppressing therapies.
Aurinia PharmaceuticalsAurinia is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Our strategy is to leverage our team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database in order to inform and guide our clinical development plans within this therapeutic area.
Avelas Biosciences, Inc.Avelas' mission is to create better outcomes for cancer patients using our proprietary platform technology of activatable cell-penetrating peptides (ACPPs). The ACPP technology exploits a cancer's inherent biochemical pathology to "unmask" itself to delivered cargo. The most advanced product candidate, AVB-620, combines the ACPP platform with a fluorescent marker to create a real-time illuminated cancer map to assist the surgical oncologist during surgery. AVB-620 is currently completing a phase 1b clinical trial in breast cancer patients.
Additionally, Avelas is advancing the ACPP platform for the targeted delivery of small molecules and other therapeutic cargo in the tumor environment, where specific enzyme activity activity is amplified. The technology should allow for enhanced tissue penetration and retention, with chemical design-flexibility enabling changes to both the enzyme targeting and payloads. Our lead candidate in the therapeutic space is AVB-754.
AVEO OncologyAVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).
Avidity Biosciences LLCAvidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is working with partners to discover best-in-class drug candidates against important undrugged therapeutic targets in oncology and other serious diseases.
Avisa Pharma Inc.Avisa is a venture-backed healthcare company commercializing a rapid, point-of-care breath test for the diagnosis of pulmonary infections. Avisa was founded by a successful serial healthcare care entrepreneur (now CEO) and is managed by an experienced senior team with a combined 6 exits in the healthcare device/diagnostic arena as well as a deep bench of clinical support on the company’s scientific advisory board featuring members from Johns Hopkins, University of Colorado, University of Alabama, St. Judes, University of Texas, Vanderbilt University, and Temple University. The company has received $10 million to date in venture and angel investment and is in the process of raising its $10-15 million Series B to take it through its first pivotal trial.
Avisa’s patented, enabling technologies enable the rapid, point-of-care detection of pulmonary infections through the use of safe, non-toxic carbon isotopes that, when metabolized by certain pathogens, release biomarkers into exhaled breath which is captured by the company’s proprietary laser spectrometry technology that compares pre and post inhalation isotope ratios to detect infection. The Avisa BreathTest is inexpensive and easy to administer, but provides critical clinical information in a timely (less than 10 minutes) and reliable fashion. This platform technology has been successfully demonstrated in pre-clinical and pilot work across a number of pulmonary indications including pneumonia, COPD, and tuberculosis. The company’s first targets are in the >$10 billion annual U.S. pneumonia market (pneumonia is the #1 cause for hospitalization of U.S. adults and children (other than childbirth) with about 1 million adults hospitalized every year and about 50,000 dying from this disease) and the company estimates that the Avisa BreathTest has a pneumonia market potential of over $1.7 billion in the U.S. alone (Europe represents another $1.4 billion and China another $3.4 billion in market potential). The Avisa BreathTest is a cost advantaged product that allows for better antibiotic stewardship to reduce the overuse of powerful, broad spectrum antibiotics (which prevents antibiotic resistant superbugs) and is a win for patients, doctors, hospitals, and payers.
Benefiting from Innovative Clinical Trial Designs: Biomarkers, Patient-Oriented Endpoints, Batch Trials, and Digital ToolsRecent analyses from BIO and from McKinsey & Company suggest higher clinical trial success rates related to use of selection biomarkers and from trial collaborations. Traditional outcomes measures are being reconsidered, by trial sponsors and regulators, to impact drug development in ways that can help patients faster while and digital tools such as Apple's ResearchKit hold promise for cheaper, bigger trials. This panel will showcase some of the latest approaches currently being used to increase success and improve productivity in clinical development.
Beth Rogozinski David Thomas, CFA Sanjay Kakkar, MD, MSC, MPH Melissa C. Paoloni, DVM, DACVIM-O Adian Power, MD, BCh, Msc, MRCPsych Komathi Stem - Moderator
BioAxone BioSciencesBioAxone BioSciences Inc. is a privately owned, clinical stage biotechnology company dedicated to developing new medicines to treat patients with neurovascular disorders and neurotrauma. BioAxone’s drug targets are based on a deep understanding of Rho signaling pathways. BioAxone’s first drug, a Rho inhibitor, now called VX-210 was out-licensed in 2014. BioAxone’s current lead drug is a small molecule that targets Rho kinase 2 (ROCK2) for treatment of Cerebral cavernomas malformation (CCM) also known as angiomas. CCMs are common cerebrovascular anomalies affecting 0.3 to 0.9% of the population that are caused by hyper-activation of ROCK upon mutation of one of 3 CCM genes. BA-1049 has remarkable efficacy in reversing ROCK hyperactivation, it is orally available, repeat doses are well tolerated, and the safety profile suggests a large therapeutic window. We seek a development partner to accelerate clinical development.
BioMarker Strategies, LLCBioMarker Strategies has developed the proprietary and recently patented SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Our mission is to make personalized medicine more of a reality for these patients.
SnapPath® is unique in automating and standardizing functional ex vivo profiling to capture the dynamic and predictive signaling information available only from live solid tumor cells.
Biosortia Pharmaceuticals, Inc.Biosortia Pharmaceuticals - accessing new frontiers for novel natural compounds to improve the lives of patients.
Biosortia Pharmaceuticals is uniquely positioned to access the richest chemistry on earth for the discovery of first-in-class small molecules as potential solutions to high priority unmet needs for human health.
Problem In the Pharmaceutical Marketplace
The Pharma industry’s prospects for growth and profitability depend on finding chemistry for unmet medical needs. Pharma currently does not have access to pre-optimized small molecule chemistry produced by unculturable aquatic microorganisms. Typical access to microorganisms through culturing is less than1% of which less than 2% of their secondary metabolites or elicited compounds are accessible. Therefore less than 1 in 5,000 compounds are traditionally accessible. Pharma’s primary challenge is the lack of novelty and redundancy of their screening libraries. Biosortia addresses the opportunity with a breakthrough capability of accessing nearly 100% of the available chemistry, unlocking a new frontier.
BioTime, Inc.BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime, Inc.’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.
BioVerity Inc.BioVerity is a natural, science based non-drug brand of 31 food ingredients developed to help people live longer, better lives.
Numerous Animal research studies with 10 published papers since 2003 by a team of scientists at McMaster University (leading Canadian University) shows this formula can:
*Extend life by 14% to 27%
*Retain 95% of peak physical ability & 100% peak mental ability until extreme old age vs a normal decline of 50%
*Reduce arthritis and glaucoma by 10 times
*Total protection of DNA damage in animals who were given high levels of radiation
*Abolish cognitive decline in a mouse model for Dementia, Alzheimer's, ALS and Parkinson's.
BioVerity was developed by the McMaster scientists to address five leading biological factors that cause aging: Oxidative stress, Inflammation, Mitochondrial Function, Insulin Resistance and Cell Membrane Integrity.
The 31 ingredients are all individually approved for sale in the US and the product can be marketed imminently. We intend to emulate the pharmaceutical development process and conduct a Phase 1 Test to ensure we do no harm. At that point we will begin marketing as a health product and concurrently conduct several human studies to validate efficacy for various conditions.
We have strong interest from several leading academics and researchers at notable US universities to conduct these studies.
These include: Cognitive Decline, Depression, Chemo Fog Protection, Radiation Protection, Longevity, Etc.
Boston Immune Technologies and TherapeuticsBoston Immune Technologies & Therapeutics, Inc. (BITT) (Boston, MA) is a biotechnology company developing a novel cancer immunotherapy platform for creating dominant tumor necrosis factor receptor 2 (TNFR2) antagonist antibodies, or DomAb™. DomAb™ target a highly enriched population of immunosuppressive regulatory T cells (Tregs) that protect tumors. DomAb™ also directly target tumors that express TNFR2, an NFkB-driven growth receptor oncogene. BITT’s technology was developed at Massachusetts General Hospital/ Harvard Medical School.
Calithera BiosciencesCalithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
Capricor Therapeutics, Inc.Capricor Therapeutics, Inc. (Nasdaq:CAPR), is a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease. Capricor Therapeutics’ lead product candidates currently target the prevention and treatment of heart failure and “myocardial infarction”, which make up a substantial portion of the $204.4 billion total estimated annual costs of cardiovascular disease in the U.S. Our lead cardiovascular programs target post myocardial infarction, heart failure and, a genetic disorder, Duchenne Muscular Dystrophy, characterized by muscle degeneration and weakness. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction, advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the company is conducting research and development on its exosomes platform technology. Endogenous to the body, exosomes are versatile nanoparticles being studied for use as therapeutic agents. Our translational approach to product development is based on the comprehensive research foundation provided through our academic partnerships with leading scientists at top-tier research institutions.
Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals is dedicated to advancing therapies targeting rare neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS), Infantile Spasms, and Tourette’s Disorder. Catalyst is an integrated pharmaceutical company with the ability to develop and market new products.
Celcuity LLCCelcuity is developing the world’s first signaling function diagnostic tests that use a patient’s live cancer cells to identify cancer sub-types genomic tests cannot detect. We are preparing to launch our first test from our CLIA certified lab towards the end of 2016.
Our approach represents a paradigm shift away from the current industry focus on creating more and more detailed, but static, snapshots of the genetic or proteomic composition of a patient’s diseased cells. These tests may identify the presence of the genes or gene products associated with a disease but they cannot assess how they function in the context of a particular individual’s diseased cells. No tests are available today that measure the underlying mechanism of a patient’s disease using their live cells.
Our long-term vision is to establish our functional cellular analysis platform as the definitive method of guiding diagnosis and selecting drug treatments for certain disease pathways. Our first diagnostic, the CELx HER2 Signaling Profile, is designed to identify a currently undiagnosable sub-type of HER2-driven breast cancer. The current method of diagnosing HER2-related breast cancer measures the expression-level of the HER2 protein. When only HER2 levels are measured, though, HER2-negative patients who have abnormal HER2 signaling activity in their tumor cells are diagnosed as not having HER2-driven breast cancer, when, in fact, they do.
Our CELx HER2 Signaling Profile test measures the HER2 signaling function in the live tumor cells of breast cancer patients to identify patients with this cancer sub-type. Based on the results of our first clinical study, we estimate that 40%-50% of HER2-driven breast cancer is undiagnosed and thus not treated with anti-HER2 therapies. Our test gives oncologists the information they need to consider treating their patients with these drugs.
An estimated 215,000 HER2-negative drug eligible breast cancer patients are candidates for our test in the United States (70% of the total), creating a potential $650 million market for this first test. Dysfunctional HER2-related pathway activity is also implicated in a portion of lung, colon, ovarian, head and neck, gastric and esophagus cancers; these cancers account for 300,000 eligible patients annually. Celcuity plans to adapt the CELx HER2 Signaling Pathway test for these cancers. The market potential for these tests is $900 million.
Cellectar Biosciences, IncCellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC Delivery Platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is actively developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.
Centogene AGCentogene is a worldwide leader in the field of genetic diagnostic testing for rare hereditary diseases, with a broad test portfolio covering over 2800 genes, biochemical tests, biomarker and clinical whole exome sequencing and whole genome sequencing.
Our mission is to unlock the power of genetic insights to improve the quality of life of patients with genetic diseases. We achieve this through:
- Knowledge created by our worldwide diagnostic testing services incorporating unprecedented global diversity
- The world’s leading, proprietary human genetic interpretation database, CentoMD®
- Solutions for pharmaceutical companies developing life-changing orphan drugs
- Achieving the highest levels of accreditation to assure the best quality in our processes
As one of the most diversified and largest genetic testing companies worldwide we are dedicated to transforming the science of genetic information into solutions and hope for patients and their families
CENTROSE LLCOur mission is finding cures for untreatable diseases.
Our focus on the chemistry and biology unique to humans led us to the creation of EDC technology, which we use to craft true precision therapies.
Cerecor, IncCerecor Inc. is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. We systematically identify platforms and product candidates for which human proof of concept exists in the intended indication, for either the target or the compound, and for which biomarkers are available to measure therapeutic response. We target conditions where we believe current treatments fail to address unmet medical needs, and where we can apply clinical strategies to increase efficacy signal detection. These strategies include using personalized therapeutic approaches and placebo mitigation techniques to facilitate regulatory approval for our product candidates.
Chimera BioTechnology, Inc.Chimera BioTechnology, Inc. is a development stage company advancing a novel hemostatic agent to treat trauma-related bleeding. Our initial focus is on the treatment of severe postpartum hemorrhage which is the leading cause of maternal mortality in the world today. By eliminating the binding to blood components that can promote thrombosis, our proprietary agent is envisioned to address the unmet medical need for a safe hemostatic agent that can be administered early in the treatment of a wide variety of trauma-related injuries to prevent life-threatening blood loss and improve clinical outcomes.
Chrysalis Therapeutics, Inc.Chrysalis Therapeutics is committed to the discovery and development of novel, life-saving cancer medicines.
We rapidly discover and develop small-molecule drugs for emerging cancer targets, including epigenetic enzymes (e.g., KDM4/5) and signaling proteins (e.g., KRAS). Our targets have been demonstrated in numerous scientific studies to be significantly altered in cancer and are known drivers of poor clinical outcomes. Targeting these biological pathways has the potential to deliver revolutionary, first-in-class treatments for cancer.
CohBarCohBar, Inc. is an innovative biotechnology company whose mission is to treat major diseases and extend healthy life spans through the discovery of novel Mitochondrial-Derived Peptides (“MDPs”) and the advancement of their development into clinically relevant and commercially successful therapeutics.
CohBar’s scientific leadership is centered on the expertise of our founders, Dr. Pinchas Cohen, Dean of the Davis School of Gerontology at the University of Southern California, and Dr. Nir Barzilai, Professor of Genetics and Director of the Institute for Aging Research at the Albert Einstein College of Medicine, and is supported by our co-founders, Dr. David Sinclair, Professor of Genetics at Harvard Medical School, and Dr. John Amatruda, former Senior Vice President and Franchise Head for Diabetes and Obesity at Merck Research Laboratories.
Colby Pharmaceutical CompanyColby Pharmaceutical Company is a private company with ofiices and laboratories in the San Francisco Bay area. The mission of the company is to preserve and improve health and well being with small molecuke pharmaceutical and biologic drugs.
ConcentrxConcentRx is a unique, early stage, biotech company, passionately focused on discovering, developing, and commercializing curative Immuno-oncology medicines in areas of huge unmet need. Our focus is on currently untreatable cancers where our unique approach may be able to address cancer patients' needs that most think cannot be met..
Pamela Contag, PhD
Correlia Biosystems, Inc.Correlia's SimpleScan is an automated platform that provides quantitative protein data sets with unparalleled speed and ease-of-use.
The SimpleScan combines an innovative hydrogel material and an electrically-driven test process to dramatically cut the time and sample volumes required for protein measurement. Results from our platform are peer-reviewed, robust and versatile. Compared to traditional bead or plate based protein tests, the SimpleScan produces results in minutes (instead of hours) and operates from less than 2 uL of biosample. These performance advantages allows users to accelerate their R&D timelines and open up new research avenues in bioscience and personalized medicine.
Corvida MedicalCorvida Medical is an emerging medical device company optimizing the safe handling of hazardous medications. We are committed to creating affordable solutions that ensure safety and improve productivity, enabling healthcare providers to deliver the highest quality care for their patients. Hospital pharmacies and oncology clinics create a $1.6 Billion worldwide market growing rapidly. Corvida has leveraged $5 million of National Cancer Institute (NCI) Small Business Innovation Research (SBIR) grants and private investments to achieve FDA 510(k) clearance and initial sales revenues. Through innovation, teamwork, and strategic partnerships, we will capture market opportunities that maximize shareholder value.
Critical Outcome Technologies Inc.COTI is a clinical stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer. The Company’s lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. COTI-2 is being initially evaluated for the treatment of gynecologic cancers, which includes ovarian, cervical, and endometrial cancers in a Phase 1 clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. The Company has secured orphan drug status in the US for COTI-2 for the treatment of ovarian cancer in patients failing first line therapies and is planning additional studies in other cancer indications such as head and neck, Li-Fraumeni Syndrome, and acute myelogenous leukemia, based upon more than ten animal xenograft models showing both single and combination agent activity of COTI-2 with other leading cancer drugs. Preclinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.
Curetis N.V.Curetis is a Molecular Diagnostics company with a focus on severe infectious disease in hospitalized patients. Our Unyvero platform is a sample to answer solution, allowing hospitals to detect pathogens and antibiotic resistance markers with just minutes of hands on time.
Curetis is commercial stage with direct sales in key European markets and in the process of setting up US operations ahead of our expected FDA trial completion in H2-2016 and expected FDA clearance of the platform in H1-2017.
Curetis also has strong partners in Asia (china and ASEAN) as well as many distribution markets around the world.
Curtana Pharmaceuticals, Inc.Curtana Pharmaceuticals, Inc., which was founded in San Diego, CA and is now headquartered in Austin, TX, is developing first-in-class small molecule therapeutics that directly target and kill cancer stem cells (CSCs) for the treatment of brain cancer, including glioblastoma (GBM) in adults and pediatric high grade glioma (pHGG) in children.
The company’s clinical candidate, CT-179, blocks the function of Olig2, a transcription factor that is highly expressed in all diffuse gliomas, but is not found in normal tissues outside the central nervous system. Olig2 is required for tumorigenesis, drives tumor invasion into healthy tissue, and promotes resistance to radiation therapy. The targeted CSCs have been shown to be immunosuppressive in the local tumor micro-environment. CT-179 can be administered orally once daily, readily crosses the blood-brain barrier, achieves very high concentrations in the brain, and, most importantly, significantly prolongs survival in a mouse brain cancer model. The filing of an IND application for CT-179 is planned to occur in H2 2017.
GBM is one of the deadliest malignant primary brain tumors in adults. In the U.S., there are approximately 10,000 new cases per year, making this an orphan indication. Standard treatment is surgery, followed by radiation therapy or combined radiation and chemotherapy with temozolomide (Temodar®). The U.S. market for the treatment of GBM and other malignant gliomas is valued at approximately $400 million per year and the world-wide market is valued at over $1 billion. There remains significant unmet clinical need in the GBM market as the median survival is less than 15 months, 2-year survival is only 30%, and 5-year survival is less than 10%.
Cyta Therapeutics Inc.Cyta is a pre-clinical stage company developing therapies for liver disease. Cyta is utilizing its "IntelliGel" platform technology to develop products to restore liver health, specifically liver regeneration and cytoprotection. The company's core technology is based on a novel chemistry platform developed by Professor Thayumanavan at the University of Massachusetts, Amherst. Cyta's IntelliGel platform is differentiated from other nano platforms due to its ability to self-assemble and tightly encapsulate drug without cargo leakage and its stimuli responsive trigger to release drug cargo. These characteristics result in an ability to develop drugs with improved therapeutic index and ease of manufacturing with elegant, but streamlined chemistry.
With the exception of the approved Hepatitis C drugs, there are few highly effective options for treating the patients with liver diseases forecasted to substantially increase over the next twenty to thirty years. In particular, non-alcoholic statohepatitis (NASH) is expected to become the leading indication for liver transplantation by 2020 and has no approved drugs on the market. Cyta is developing a product which will reduce inflammation and stimulate liver regeneration thereby providing protection and restoration of normal liver function.
Cyta is seeking to raise a Series A financing to reach its first value creating milestone demonstrating in vivo proof of concept in disease relevant animal models.
CytoSavvyCytoSavvy is a software development company targeting automation of cancer grading applications that are currently performed 100% manually: renal cell carcinoma (RCC), prostate, breast, and bladder cancer, representing nearly one-half of the most common U.S. cancers. Advances in automated microscopy have resulted in an explosion of digital imagery data requiring analysis that is beyond human capabilities. CytoSavvy is developing novel shape based modeling segmentation (SBMS) software for automated analysis of digital pathology imagery that will be supported by a one of a kind internet-based business designed to collect data and make a decision for final approval. The software uses unique algorithms to more effectively find and interpret intracellular structures and can reduce manual analysis costs by over 80%.